The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
about
Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticRuxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROSMulti-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.Aberrant Expression Profile of Long Noncoding RNA in Human Sinonasal Squamous Cell Carcinoma by Microarray Analysis.[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
P2860
Q36995729-AB67D685-7D05-46D4-8AB5-BACAC47AA28AQ37109457-86FA07FF-01D9-4D30-BF70-8BD61CAC150EQ37457895-90EB673A-73F2-45EF-9576-87C4C9A9BD67Q37706510-41D27597-CEBF-4CC9-973A-84B4751ECFD6Q38438504-313C3D29-1741-4EBF-86F0-BB97B1F56EDEQ38622540-51D32670-4D57-46DF-8FDB-90FF493FE1C8Q38721255-860C7952-5691-4D9F-BB24-83CCA33CB5D2Q39888747-008A637D-221E-4DA0-B7F9-C015BCEFEE97Q41116584-F9C4D711-0195-4034-AABB-1BC59CEDB115Q42378470-189808DF-AD12-43D6-8722-078819CEDB13Q45073629-85F030D4-BCAA-4F75-BF49-1B4DD0D91FCCQ46301742-DEEE381E-948E-4B1B-9CEC-BAE1E278FB23Q47146662-96C29CF2-9E31-414C-ABB0-38144956147AQ49787645-C41EAB6F-9896-41A0-B1B1-63DBA3840B63Q50187396-55BEDAC9-F0EC-4CA8-8660-346E640F3F7DQ57177486-DE4D5876-FAD2-4B5C-A8C1-102B8BD6780E
P2860
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The afatinib resistance of in ...... mpensatory survival signaling.
@en
The afatinib resistance of in ...... mpensatory survival signaling.
@nl
type
label
The afatinib resistance of in ...... mpensatory survival signaling.
@en
The afatinib resistance of in ...... mpensatory survival signaling.
@nl
prefLabel
The afatinib resistance of in ...... mpensatory survival signaling.
@en
The afatinib resistance of in ...... mpensatory survival signaling.
@nl
P2093
P2860
P356
P1433
P1476
The afatinib resistance of in ...... mpensatory survival signaling.
@en
P2093
Andrew Poklepovic
Daniel Leon
Jane L Roberts
Jesse Chen
Laurence Booth
Mehrad Tavallai
Timothy Webb
William P McGuire
P2860
P304
19620-19630
P356
10.18632/ONCOTARGET.7746
P407
P50
P577
2016-02-26T00:00:00Z